

## Nomination Committee appointed for the Annual General Meeting 2023 in LIDDS

UPPSALA, SWEDEN – LIDDS AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2023. The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of the Chairman of the Board and three representatives for the two largest shareholders.

The main task of the Nomination Committee is to submit proposals for Chairman of the Board and other members of the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of the Chairman of the Board and members appointed by the two largest shareholders in the company based on ownership of the Company as per the end of September 2022.

Accordingly, the following committee members have been appointed:

- Bengt-Åke Bengtsson, Chairman
- Olle Isaksson
- Bengt Viterius
- Jan Törnell, Chairman of LIDDS Board of Directors

The Nomination Committee's proposals will be presented in the Notice to the Annual General Meeting 2023 and on the company web site, [www.liddspharma.com](http://www.liddspharma.com). Shareholders desiring to submit comments or proposals to the nomination committee can send them via e-mail to [info@liddspharma.com](mailto:info@liddspharma.com).

**For additional information, please contact**

---

Anders Månsson, CEO  
Phone: +46 (0)70 860 47 38  
E-mail: [anders.mansson@liddspharma.com](mailto:anders.mansson@liddspharma.com)

Jenni Björnulfson, CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

**LIDDS in brief:**

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

**Attachments****Nomination Committee appointed for the Annual General Meeting 2023 in LIDDS**